Effects of CD8+CD28- T suppressor lymphocyte (Ts) on B- and T-lymphocyte function in systemic lupus erythematosus (SLE)

published_or_final_versio

Drug therapy in rheumatoid arthritis

Rheumatoid arthritis is such a debilitating illness that much effort has been made to find the ideal therapeutic regimen that has a high efficacy but low toxicity rate. Although such regimen has not been found yet, judicious use of what are currently available can improve the outcome of many of our patients.published_or_final_versio

Leflunomide (LEF) versus low dose methotrexate (MTX) in adult Asian patients with active rheumatoid arthritis (RA)

published_or_final_versio

Antirheumatic drug prescribing pattern: a survey of Hong Kong physicians

published_or_final_versio

Intestinal pseudoobstruction is an uncommon but important clinical manifestation of systemic lupus erythematosus (SLE)

published_or_final_versio

Neuropsychiatric manifestations in southern Chinese patients with systemic lupus erythematosus (SLE) according to the 1999 ACR nomenclature and their clinical associations

published_or_final_versio

A new model of health identified through qualitative and quantitative analysis of the Chinese Arthritis Impact Measurement Scales 2. Cultural issues in the translation and validation of health status measures

published_or_final_versio

Management strategies for systemic lupus erythematosus

The management of systemic lupus erythematosus (SLE) is a challenging task. All interventions to-date are palliative rather than curative as the pathogenesis of the disease remains enigmatic. Treatment-related side effects can be as problematic as the disease itself. The following is a review of the practical management of the disease based on our experience.published_or_final_versio

The effects of topical triptolide in an animal model of contact dermatitis

published_or_final_versio

The use of anti-ribosomal P antibodies in the diagnosis of cerebral lupus: superiority of western blotting over enzyme-linnked immunosorbent assay

This study investigated the use of anti-ribosomal P antibodies in the diagnosis of cerebral complications of systemic lupus erythematosus using two different methodsԸ?western blotting and enzyme-linked immunosorbent assay. Anti-ribosomal P antibodies in patient serum were detected in both methods using a purified ribosomal P antigen substrate. Western blotting detected anti-ribosomal P antibodies with a 90% specificity for systemic lupus erythematosus in 56% of patients with the disease. The detection of anti-ribosomal P antibodies by western blotting in patients with systemic lupus erythematosus was significantly associated with psychosis and/or seizures; detection was positive in 90% of patients with these cerebral complications and in 41% of those without. Elevation of the level of anti-ribosomal P antibody, as measured by enzyme-linked immunosorbent assay, was 99% specific for systemic lupus erythematosus in 44% of patients with systemic lupus erythematosus that was not associated with cerebral involvement. We conclude that the measurement of anti-ribosomal P antibodies by western blotting is helpful in the diagnosis of cerebral lupus in selected patients.published_or_final_versio